Whittier Trust Co. of Nevada Inc. Sells 1,945 Shares of Johnson & Johnson (JNJ)

Whittier Trust Co. of Nevada Inc. lowered its position in shares of Johnson & Johnson (NYSE:JNJ) by 1.2% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 161,650 shares of the company’s stock after selling 1,945 shares during the period. Johnson & Johnson comprises about 2.0% of Whittier Trust Co. of Nevada Inc.’s portfolio, making the stock its 4th biggest position. Whittier Trust Co. of Nevada Inc.’s holdings in Johnson & Johnson were worth $21,016,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently modified their holdings of JNJ. Harding Loevner LP bought a new stake in shares of Johnson & Johnson in the 2nd quarter valued at about $106,000. Mitsubishi UFJ Securities Holdings Co. Ltd. grew its position in shares of Johnson & Johnson by 29.9% in the 2nd quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 870 shares of the company’s stock valued at $115,000 after buying an additional 200 shares during the last quarter. Lenox Wealth Advisors Inc. grew its position in shares of Johnson & Johnson by 0.6% in the 2nd quarter. Lenox Wealth Advisors Inc. now owns 876 shares of the company’s stock valued at $116,000 after buying an additional 5 shares during the last quarter. IHT Wealth Management LLC grew its position in shares of Johnson & Johnson by 46.4% in the 2nd quarter. IHT Wealth Management LLC now owns 10,942 shares of the company’s stock valued at $122,000 after buying an additional 3,467 shares during the last quarter. Finally, Mountain Capital Investment Advisors Inc bought a new stake in shares of Johnson & Johnson in the 2nd quarter valued at about $124,000. Institutional investors and hedge funds own 65.70% of the company’s stock.

Johnson & Johnson (JNJ) opened at $140.56 on Friday. The stock has a market capitalization of $377,644.13, a PE ratio of 24.40, a PEG ratio of 2.86 and a beta of 0.80. The company has a debt-to-equity ratio of 0.36, a current ratio of 1.32 and a quick ratio of 1.02. Johnson & Johnson has a 52 week low of $110.76 and a 52 week high of $144.35.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, October 17th. The company reported $1.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.80 by $0.10. Johnson & Johnson had a return on equity of 27.38% and a net margin of 21.28%. The company had revenue of $19.65 billion for the quarter, compared to the consensus estimate of $19.29 billion. During the same period in the previous year, the business earned $1.68 EPS. The firm’s revenue was up 10.3% compared to the same quarter last year. sell-side analysts predict that Johnson & Johnson will post 7.28 earnings per share for the current fiscal year.

The company also recently declared a quarterly dividend, which was paid on Tuesday, December 12th. Investors of record on Tuesday, November 28th were paid a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a yield of 2.39%. The ex-dividend date of this dividend was Monday, November 27th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 58.33%.

JNJ has been the topic of a number of analyst reports. Cowen reiterated an “outperform” rating and issued a $155.00 price target (up previously from $147.00) on shares of Johnson & Johnson in a research report on Wednesday, October 18th. UBS Group reiterated a “buy” rating and issued a $148.00 price target on shares of Johnson & Johnson in a research report on Thursday, August 31st. Jefferies Group upped their price target on Johnson & Johnson from $157.00 to $160.00 and gave the company a “buy” rating in a research report on Monday, October 16th. Zacks Investment Research upgraded Johnson & Johnson from a “sell” rating to a “hold” rating in a research report on Wednesday, October 4th. Finally, Credit Suisse Group set a $154.00 price objective on Johnson & Johnson and gave the company an “outperform” rating in a research note on Thursday, October 19th. Four equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and eleven have assigned a buy rating to the stock. The stock has an average rating of “Hold” and a consensus price target of $145.47.

TRADEMARK VIOLATION WARNING: This piece of content was first posted by Community Financial News and is owned by of Community Financial News. If you are accessing this piece of content on another site, it was illegally copied and reposted in violation of U.S. and international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.com-unik.info/2017/12/29/whittier-trust-co-of-nevada-inc-sells-1945-shares-of-johnson-johnson-jnj.html.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

What are top analysts saying about Johnson & Johnson? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Johnson & Johnson and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit